Spyre Therapeutics stock rises after crossing above SMA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2024
0mins
Should l Buy SYRE?
Spyre Therapeutics Inc's stock rose by 5.03% during regular trading as it crossed above its 5-day SMA, indicating positive momentum in the stock's performance.
Despite the S&P 500's slight decline of 0.18%, Spyre's stock movement can be attributed to sector rotation, as investors are shifting their focus towards biotech stocks amid broader market conditions. The Nasdaq-100's increase of 0.43% suggests a favorable environment for growth-oriented sectors, benefiting Spyre.
This upward movement reflects investor confidence in the biotech sector, potentially driven by recent advancements in drug development and a positive outlook for the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYRE
Wall Street analysts forecast SYRE stock price to fall
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 74.450
Low
40.00
Averages
56.67
High
70.00
Current: 74.450
Low
40.00
Averages
56.67
High
70.00
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Spyre Therapeutics (SYRE.US) Officer Plans to Sell $5.83 Million in Common Stock via Form 144
Share Sale Announcement: Sheldon Sloan plans to sell 78,333 shares of Spyre Therapeutics (SYRE.US) on May 1, with an estimated market value of approximately $5.83 million.
Reduction in Holdings: Since April 1, 2026, Sheldon Sloan has reduced his shareholding in Spyre Therapeutics by 7,958 shares, valued at around $397.9K.
See More
Spyre Therapeutics Grants Stock Options to Employees
- Stock Option Grant: On May 1, 2026, Spyre Therapeutics approved the grant of stock options totaling 20,800 shares to four non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Option Terms: The stock options have an exercise price of $69.42 per share, in compliance with Nasdaq listing rules, with a 10-year term; employees can exercise one-fourth of the options on their first anniversary and one-fortieth monthly thereafter, ensuring alignment of employee tenure with company growth.
- Strategic Implications: By implementing stock option incentives, Spyre not only enhances employee loyalty and commitment but also fosters innovation and development in the fields of inflammatory bowel disease and rheumatic diseases through performance-linked incentives.
- Company Overview: Spyre Therapeutics focuses on developing long-acting antibodies and combinations to redefine treatment standards for inflammatory bowel disease and rheumatic diseases, with a pipeline that includes investigational antibodies targeting α4β7, TL1A, and IL-23, indicating strong market potential.
See More
Spyre Therapeutics Prices Public Offering at $62 per Share
- Offering Size: Spyre Therapeutics has priced its public offering at $62.00 per share for 6.50 million shares, expecting gross proceeds of approximately $403 million, which will significantly bolster its funding for developing next-generation treatments for immune-mediated diseases.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, reflecting strong market confidence in Spyre and support for its future growth prospects.
- Stock Performance: SYRE has traded between $12.04 and $75.00 over the past year, closing at $64.01, and despite a 1.97% decline in after-hours trading, the overall performance indicates positive investor sentiment.
- Research Pipeline: Spyre's pipeline includes investigational extended half-life antibodies such as SPY001, SPY002, SPY003, and SPY072, with combination programs that will further drive innovation in treating inflammatory bowel disease, enhancing its competitive position in the market.
See More
Spyre Therapeutics Upsizes Public Offering to Raise $403 Million
- Upsized Offering: Spyre Therapeutics has announced an upsized public offering of 6.5 million shares at $62.00 each, aiming to raise approximately $403 million, exceeding the initial target of $300 million, indicating strong market demand for its stock.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional $60.5 million in shares at the same price, providing the company with potential for further capital infusion and enhancing its financial flexibility.
- Expected Closing Date: The offering is expected to close around April 16, 2026, allowing the company ample time to optimize the use of funds to support future research and market expansion initiatives.
- Positive Market Sentiment: The strong data from Spyre Therapeutics and upcoming clinical trial results provide a favorable backdrop for this offering, likely boosting investor confidence and driving the company's stock price upward.
See More
Spyre Therapeutics Prices $403 Million Public Offering
- Offering Size: Spyre Therapeutics has announced a public offering of 6,500,000 shares at $62.00 per share, expected to raise approximately $403 million in gross proceeds, which will significantly bolster the company's funding for R&D and market expansion.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, reflecting strong market confidence in Spyre and potentially enhancing the company's reputation in the biotechnology sector.
- Additional Purchase Option: The company has granted underwriters a 30-day option to purchase an additional approximately $60.5 million of shares at the public offering price, which may further enhance liquidity and support future growth initiatives.
- Compliance and Transparency: Spyre has filed a registration statement with the SEC and published a preliminary prospectus on the SEC website, ensuring investors have access to transparent information, thereby increasing market trust.
See More
Spyre Therapeutics Prices Public Offering at $62 per Share
- Offering Size: Spyre Therapeutics announced a public offering of 6,500,000 shares at $62.00 per share, expected to raise approximately $403 million, demonstrating the company's strong fundraising capability in the biotechnology sector.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, indicating the company's credibility and attractiveness in the capital markets.
- Additional Purchase Option: The company granted underwriters a 30-day option to purchase an additional approximately $60.5 million of shares at the public offering price, which may further enhance the company's liquidity.
- Compliance and Transparency: Spyre has filed a registration statement with the SEC and received approval, ensuring compliance for the offering, which boosts investor confidence and promotes market interest in its future products.
See More
Spyre Therapeutics (SYRE.US) Officer Plans to Sell $5.83 Million in Common Stock via Form 144
Share Sale Announcement: Sheldon Sloan plans to sell 78,333 shares of Spyre Therapeutics (SYRE.US) on May 1, with an estimated market value of approximately $5.83 million.
Reduction in Holdings: Since April 1, 2026, Sheldon Sloan has reduced his shareholding in Spyre Therapeutics by 7,958 shares, valued at around $397.9K.
See More
Spyre Therapeutics Grants Stock Options to Employees
- Stock Option Grant: On May 1, 2026, Spyre Therapeutics approved the grant of stock options totaling 20,800 shares to four non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Option Terms: The stock options have an exercise price of $69.42 per share, in compliance with Nasdaq listing rules, with a 10-year term; employees can exercise one-fourth of the options on their first anniversary and one-fortieth monthly thereafter, ensuring alignment of employee tenure with company growth.
- Strategic Implications: By implementing stock option incentives, Spyre not only enhances employee loyalty and commitment but also fosters innovation and development in the fields of inflammatory bowel disease and rheumatic diseases through performance-linked incentives.
- Company Overview: Spyre Therapeutics focuses on developing long-acting antibodies and combinations to redefine treatment standards for inflammatory bowel disease and rheumatic diseases, with a pipeline that includes investigational antibodies targeting α4β7, TL1A, and IL-23, indicating strong market potential.
See More
Spyre Therapeutics Prices Public Offering at $62 per Share
- Offering Size: Spyre Therapeutics has priced its public offering at $62.00 per share for 6.50 million shares, expecting gross proceeds of approximately $403 million, which will significantly bolster its funding for developing next-generation treatments for immune-mediated diseases.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, reflecting strong market confidence in Spyre and support for its future growth prospects.
- Stock Performance: SYRE has traded between $12.04 and $75.00 over the past year, closing at $64.01, and despite a 1.97% decline in after-hours trading, the overall performance indicates positive investor sentiment.
- Research Pipeline: Spyre's pipeline includes investigational extended half-life antibodies such as SPY001, SPY002, SPY003, and SPY072, with combination programs that will further drive innovation in treating inflammatory bowel disease, enhancing its competitive position in the market.
See More
Spyre Therapeutics Upsizes Public Offering to Raise $403 Million
- Upsized Offering: Spyre Therapeutics has announced an upsized public offering of 6.5 million shares at $62.00 each, aiming to raise approximately $403 million, exceeding the initial target of $300 million, indicating strong market demand for its stock.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional $60.5 million in shares at the same price, providing the company with potential for further capital infusion and enhancing its financial flexibility.
- Expected Closing Date: The offering is expected to close around April 16, 2026, allowing the company ample time to optimize the use of funds to support future research and market expansion initiatives.
- Positive Market Sentiment: The strong data from Spyre Therapeutics and upcoming clinical trial results provide a favorable backdrop for this offering, likely boosting investor confidence and driving the company's stock price upward.
See More
Spyre Therapeutics Prices $403 Million Public Offering
- Offering Size: Spyre Therapeutics has announced a public offering of 6,500,000 shares at $62.00 per share, expected to raise approximately $403 million in gross proceeds, which will significantly bolster the company's funding for R&D and market expansion.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, reflecting strong market confidence in Spyre and potentially enhancing the company's reputation in the biotechnology sector.
- Additional Purchase Option: The company has granted underwriters a 30-day option to purchase an additional approximately $60.5 million of shares at the public offering price, which may further enhance liquidity and support future growth initiatives.
- Compliance and Transparency: Spyre has filed a registration statement with the SEC and published a preliminary prospectus on the SEC website, ensuring investors have access to transparent information, thereby increasing market trust.
See More
Spyre Therapeutics Prices Public Offering at $62 per Share
- Offering Size: Spyre Therapeutics announced a public offering of 6,500,000 shares at $62.00 per share, expected to raise approximately $403 million, demonstrating the company's strong fundraising capability in the biotechnology sector.
- Underwriter Selection: The offering is managed by Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities, indicating the company's credibility and attractiveness in the capital markets.
- Additional Purchase Option: The company granted underwriters a 30-day option to purchase an additional approximately $60.5 million of shares at the public offering price, which may further enhance the company's liquidity.
- Compliance and Transparency: Spyre has filed a registration statement with the SEC and received approval, ensuring compliance for the offering, which boosts investor confidence and promotes market interest in its future products.
See More
